Caligan Partners LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.63B2026 Q3
Positions26
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.78.9%
What Changed This Quarter?
Top Holdings
RVMD
Revolution Medicines
24.6%
LQDA
Liquidia
15.0%
ABVX
Abivax S.A.
9.4%
PCVX
Vaxcyte
7.6%
EXEL
Exelixis
5.6%
TNGX
Tango Therapeutics
3.8%
ADMA
Adma Biologics
3.6%
IMCR
Immunocore
3.1%
New / Increased
3 new · 11 increased
OBXNEW
Obsidian Therapeutics
0.7%
EPRXNEW
Eupraxia Pharmaceuticals
0.6%
Tcgx Acquisit…NEW
TCGX Acquisition
0.2%
IMCR
Immunocore
3.1%
+21.1%
FTH
Faeth Therapeutics
1.6%
+41.4%
IVA
Inventiva
2.1%
+12.5%
SGMT
Sagimet Biosciences
1.7%
+11.8%
SABS
SAB Biotherapeutics
1.7%
+9.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.